James Salwitz, MD
Medical Oncology · East Brunswick, NJNPI 1811986706
Payments from drug & device makers
Across 62 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$154
- E.r. Squibb & Sons, L.L.C.$146
- Karyopharm Therapeutics Inc.$137
- ASD Specialty Healthcare, LLC$117
- Blueprint Medicines Corporation$108
- Amgen$104
- plus $697 from 25 others
What the payments were for
- Food & beverage$1,45099%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $154 |
| E.r. Squibb & Sons, L.L.C. | 4 | $146 |
| Karyopharm Therapeutics Inc. | 2 | $137 |
| ASD Specialty Healthcare, LLC | 2 | $117 |
| Blueprint Medicines Corporation | 2 | $108 |
| Amgen | 2 | $104 |
| AbbVie | 6 | $101 |
| Bristol Myers Squibb | 4 | $65 |
| Pfizer | 3 | $58 |
| Novartis | 2 | $41 |
| Gilead | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
| Astellas Pharma US Inc | 2 | $35 |
| AVEO Pharmaceuticals, Inc. | 1 | $28 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Mirati Therapeutics, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $21 |
| GSK | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Exelixis Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Spectrum Pharmaceuticals Inc. | 1 | $16 |
| Verastem, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Octapharma USA, Inc. | 1 | $15 |
| Cornerstone Specialty Network LLC | 10 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,462 in reported general payments places this provider in the 30th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 40 | $547,620 |
| IbrancePalbociclib | 31 | $451,197 |
| VenclextaVenetoclax | 22 | $302,912 |
| CalquenceAcalabrutinib Maleate | 20 | $290,125 |
| Lenalidomide | 18 | $269,290 |
| AfinitorEverolimus | 14 | $261,024 |
| Somatuline DepotLanreotide Acetate | 25 | $225,480 |
| RevlimidLenalidomide | 12 | $207,075 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $158,190 |
| AranespDarbepoetin Alfa In Polysorbat | 58 | $138,628 |
| Lupron DepotLeuprolide Acetate | 20 | $106,874 |
| ProcritEpoetin Alfa | 60 | $104,679 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $90,638 |
| NeulastaPegfilgrastim | 14 | $89,040 |
| PromactaEltrombopag Olamine | 12 | $84,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Octagam, Eliquis, Ruxience | $58 | $638,407116 claims |
| AbbVieVenclexta, Lupron Depot | $101 | $409,78642 claims |
| NovartisAfinitor, Promacta | $41 | $345,08326 claims |
| AstraZenecaCalquence | $16 | $290,12520 claims |
| AmgenAranesp, Neulasta | $104 | $227,66872 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $36 | $225,48025 claims |
| Bristol Myers SquibbRevlimid | $65 | $207,07512 claims |
| Johnson & JohnsonProcrit, Xarelto | $21 | $145,54993 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $21 | $16,35917 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $42230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in East Brunswick
- Edward LicitraEast Brunswick$241K
- Michael NissenblattEast Brunswick$23K
- Martin GutierrezHackensack$41.8M
- James McCloskeyHackensack$17.1M
- Lori LeslieHackensack$11.9M
- Tatyana FeldmanHackensack$8.4M
- Benjamin FreemanMorristown$7.5M
- Kristen SpencerNew Brunswick$7.2M
- David SiegelHackensack$6.9M
- Biren SaraiyaNew Brunswick$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.